← Back to blog
ValueMay 18, 2026

Buy the Dip Monday: 111% ROIC, 60% Revenue Growth, and the Natural Gas Add Insiders Made in April

Top 5 Pixie Picks

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Value stocks.

Sign in

6. GSK plc (GSK)

P/E: 12.9 | Earnings yield: 7.8% | 52w drawdown: -19.5%

GSK delivers a 20% ROIC and 72% gross margin while growing revenue 4.1% year-over-year, metrics that reflect a mature pharma with blockbuster drug cash flow and R&D optionality, and the 7.8% earnings yield against a 3.6% dividend yield provides a 2.2× payout cover while the 4.8% FCF yield underwrites the distribution. The 16.1% analyst upside to $57.66 and 19% drawdown frame the entry as strong-entry territory where valuation meets operational stability.

Insiders held flat over six months with zero net share transactions, a neutral signal that avoids the red flag of heavy selling but also lacks the conviction signal of executive adds. Short interest of 0.3% is negligible.

The 19× EV/EBITDA and 1.17 debt-to-equity ratio are elevated for a large-cap pharma, and the normalized 10-year P/E of 14.5 sits only 12% above the current 12.9 multiple, a narrow gap that suggests the stock is trading near fair value on a long-cycle basis; investors here are betting on pipeline execution or M&A rather than a deep valuation discount, and any Zantac litigation headline or Benlysta sales miss could re-open the drawdown.

7. Incyte Corporation (INCY)

P/E: 13.5 | Earnings yield: 7.4% | 52w drawdown: -14.7%

INCY prints a 111% ROIC and 93% gross margin while growing revenue 21% year-over-year, a combination that reflects Jakafi franchise cash flow funding pipeline expansion, and the 7.0% FCF yield at a 15% drawdown frames the entry as a moderate-dip zone where growth momentum meets technical support. The normalized 10-year earnings yield of 2.8% sits 62% below the current 7.4%, a spread that reflects either depressed multiples or elevated near-term profitability that consensus expects to normalize.

Insiders added $5.22 million over six months, net 161,943 shares, with CEO Pablo Cagnoni, CFO Suketu Upadhyay, and Baker Bros. Advisors each filing Form 4 purchases in April and May 2026, a 9.3-to-4.8 basis-point buy-sell ratio that signals alignment as the company navigates post-Jakafi growth through opzelura, retifanlimab, and earlier-stage assets. Short interest of 6.8% adds a positioning layer if pipeline readouts surprise positive.

⬡ Incyte announced more than 20 abstracts accepted for the European Hematology Association 2026 Congress, a breadth of data that reflects pipeline momentum across hematology and oncology, while the CEO stated that the post-Jakafi growth path is clearer as pipeline catalysts build, framing the setup as a bet on execution visibility rather than a single binary event. The 13.3% analyst upside to $108.50 prices in incremental pipeline success.

8. Gilead Sciences, Inc. (GILD)

P/E: 17.6 | Earnings yield: 5.7% | 52w drawdown: -17.6%

GILD delivers a 24% ROIC and 79% gross margin while growing revenue 2.4% year-over-year, a profile that reflects HIV franchise stability funding oncology and antiviral pipeline expansion, and the 5.9% FCF yield at a 17.6% drawdown frames the entry as strong-entry territory where cash generation meets technical support. The 22% analyst upside to $157.96 and 2.5% dividend yield provide downside cushion while the company navigates patent cliffs and pipeline execution.

Insiders added $6.09 million over six months, net 274,285 shares, with 53% of insider transactions by dollar value on the buy side against 31% on the sell side, a 5.3-to-3.1 ratio that reflects executive confidence as the company reported Q1 results; directors Harish Manwani, Kelly Kramer, and Jeffrey Bluestone each filed Form 4 purchases in May 2026. Short interest of 1.9% is low.

The 12× EV/EBITDA and 98% debt-to-equity ratio are elevated for a large-cap biopharma, and the normalized 10-year P/E of 34.1 sits 93% above the current 17.6 multiple, a gap that reflects either a structural re-rating lower after patent expirations or depressed current earnings that may not persist; investors here are betting on HIV franchise durability and oncology pipeline optionality, and any Trodelvy or Veklury sales miss could extend the drawdown.


What to Watch

AMAL earnings (next quarterly report expected early June 2026): revenue growth trajectory and net interest margin expansion will clarify whether the 11.3% FCF yield is sustainable or front-loaded from a one-time gain.

EQT and natural gas pricing (Henry Hub futures through summer 2026): sustained $3+ pricing is required to validate the 60% revenue growth rate and support the 24% analyst upside; LNG export capacity announcements or weather-driven demand shifts could re-rate the stock.

Incyte EHA Congress abstracts (June 2026): 20+ data presentations will provide visibility into post-Jakafi pipeline depth and could serve as a catalyst if retifanlimab or opzelura data exceed expectations.

FSLR and GILD quarterly earnings (July and August 2026 respectively): module ASP trends for First Solar and HIV franchise resilience for Gilead will determine whether current FCF yields reflect durable cash generation or cyclical peaks.


Go Deeper

The Buy the Dip screener isolates drawdowns where valuation, profitability, and insider conviction converge.
Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Sign in

Stock Pixie Pro

See the full Buy the Dip screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.